Latest news with #Altimmune
Associated Press
4 days ago
- Business
- Associated Press
ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--Jul 19, 2025-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Altimmune, Inc. ('Altimmune' or 'the Company') (NASDAQ: ALT ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Altimmune announced 'topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH),' on June 26, 2025. Although the Company characterized the results as 'positive,' it added that 'the effects on fibrosis improvement without worsening of MASH in an ITT analysis were 31.8% and 34.5% for pemvidutide 1.2 mg and 1.8 mg, respectively compared with 25.9% for placebo (differences not statistically significant).' Based on this news, shares of Altimmune fell by 52.18% on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at [email protected]. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. View source version on CONTACT: The Schall Law Firm Brian Schall, Esq. 310-301-3335 [email protected] KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL SOURCE: The Schall Law Firm Copyright Business Wire 2025. PUB: 07/19/2025 02:30 PM/DISC: 07/19/2025 02:30 PM
Business Wire
4 days ago
- Business
- Business Wire
ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Altimmune, Inc. ('Altimmune' or 'the Company') (NASDAQ: ALT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Altimmune announced "topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH)," on June 26, 2025. Although the Company characterized the results as 'positive,' it added that 'the effects on fibrosis improvement without worsening of MASH in an ITT analysis were 31.8% and 34.5% for pemvidutide 1.2 mg and 1.8 mg, respectively compared with 25.9% for placebo (differences not statistically significant)." Based on this news, shares of Altimmune fell by 52.18% on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Insider
28-06-2025
- Business
- Business Insider
Jefferies says market reaction to IMPACT data is overkill
Jefferies believes Altimmune (ALT) stock dropping 50% after the company announced results from its IMPACT study is overkill, as data met the firm's most likely scenario. Jefferies sees pemvidutide as a viable/safe drug uniquely positioned in MASH as the first incretin to hit statistical significance on histology at 24 weeks with potential to deepen with time and thinks these factors differentiate the drug from the fibroblast growth factor 21 class, the firm told investors in a research note. Jefferies added that the company can take meaningful share in the growing MASH market if successful. The firm reiterated a Buy rating and $28 price target on shares. Confident Investing Starts Here:
Economic Times
26-06-2025
- Business
- Economic Times
Altimmune's stock plummets over 60% as liver drug falls short in trial
Altimmune stock took a huge hit after its liver disease drug, pemvidutide, failed to show strong results in reducing fibrosis during a key MASH trial. While it helped with MASH resolution and weight loss, the lack of clear fibrosis improvement spooked investors. Shares crashed over 60%, sending shockwaves through the biotech market. Investors are now waiting for FDA feedback and the next steps for pemvidutide. With MASH being a major health issue and no approved treatment yet, all eyes are on how Altimmune moves forward. This could still be a game-changer—or a missed opportunity. Altimmune stock plummeted after disappointing MASH trial results, causing panic among investors. Despite hitting MASH resolution goals, the lack of fibrosis improvement pushed shares down 60%. Here's what went wrong—and what's next for pemvidutide and Altimmune's future. Tired of too many ads? Remove Ads What is the current stock price of Altimmune? Current price: $7.71 $7.71 52-week high: $11.16 $11.16 52-week low: $3.55 $3.55 Market cap: Estimated between $558 million to $625 million Did pemvidutide meet its primary endpoint? Tired of too many ads? Remove Ads 59.1% of patients on the 1.2 mg dose saw MASH resolution of patients on the 1.2 mg dose saw MASH resolution 52.1% achieved resolution on the 1.8 mg dose achieved resolution on the 1.8 mg dose Only 19.1% on placebo met this benchmark What about weight loss and secondary benefits? 5.0% weight loss at 1.2 mg at 1.2 mg 6.2% at 1.8 mg, compared to 1.0% in placebo Why did the stock crash despite positive results? Are analysts still bullish on Altimmune? What are the short-term stock trends for ALT? Tired of too many ads? Remove Ads What is MASH treatment? What's next for Altimmune and pemvidutide? FAQs: Altimmune's stock (NASDAQ: ALT) plunged roughlyin pre-market trading today after it announced mixed results from its mid-stage (IMPACT Phase 2b) trial evaluating its liver drug,, for metabolic dysfunction-associated steatohepatitis (MASH).The drug showed promising results in reducing liver fat and achieving MASH resolution, but failed to deliver strong statistical evidence for fibrosis improvement—a key benchmark in this disease of, Altimmune is trading at. This price represents a significant pullback from its recent highs, though it remains above its 52-week The trial hit its primary goal: resolution of MASH without worsening liver fibrosis. At 24 weeks:These results were statistically significant and well above expectations, positioning pemvidutide as a serious contender in the MASH also highlighted significant weight loss among trial participants:This positions pemvidutide alongside other GLP-1 class weight-loss drugs, a category currently generating high investor and consumer issue lies with the fibrosis endpoint. While there were improvements, the trial didn't reach statistical significance in its primary analysis of fibrosis reduction—a major goal in MASH treatment. Though an AI-assisted analysis showed 30.6% of patients had ≥60% reduction in fibrosis (vs. 8.2% placebo), it wasn't enough to reassure investors looking for definitive progress in this despite the sell-off, Wall Street remains optimistic about Altimmune's long-term prospects. The stock currently holds afrom suggests potential upside of nearlyfrom the current price level, assuming pemvidutide regains investor confidence in later ALT has been highly volatile and is currently trading in the. Short-term charts show, with some analysts recommending caution until the stock finds support or short for Metabolic dysfunction-associated steatohepatitis, is the new name for what was previously called NASH (Non-Alcoholic Steatohepatitis). It's a serious form of fatty liver disease that occurs when fat builds up in the liver and causes inflammation and liver cell damage, potentially leading to fibrosis, cirrhosis, or even liver will hold an investor webcast to discuss results and plans to meet the FDA for an End-of-Phase 2 meeting by late 2025. A Phase 3 trial is still under stock crashed after its MASH drug failed to show strong results in improving liver the company plans to meet the FDA and may start a Phase 3 trial.
Time of India
26-06-2025
- Business
- Time of India
Altimmune's stock plummets over 60% as liver drug falls short in trial
Altimmune's stock (NASDAQ: ALT) plunged roughly 60–64% in pre-market trading today after it announced mixed results from its mid-stage (IMPACT Phase 2b) trial evaluating its liver drug, pemvidutide , for metabolic dysfunction-associated steatohepatitis (MASH). The drug showed promising results in reducing liver fat and achieving MASH resolution, but failed to deliver strong statistical evidence for fibrosis improvement—a key benchmark in this disease area. What is the current stock price of Altimmune? As of June 26, 2025 , Altimmune is trading at $7.71 per share . This price represents a significant pullback from its recent highs, though it remains above its 52-week low. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Join new Free to Play WWII MMO War Thunder War Thunder Play Now Undo Current price: $7.71 52-week high: $11.16 52-week low: $3.55 Market cap: Estimated between $558 million to $625 million Also Read: US stock futures rise: Dow, S&P 500, and Nasdaq edge higher as Nvidia, BlackBerry, and QuantumScape rally Did pemvidutide meet its primary endpoint? Yes. The trial hit its primary goal: resolution of MASH without worsening liver fibrosis. At 24 weeks: Live Events 59.1% of patients on the 1.2 mg dose saw MASH resolution 52.1% achieved resolution on the 1.8 mg dose Only 19.1% on placebo met this benchmark These results were statistically significant and well above expectations, positioning pemvidutide as a serious contender in the MASH space. Also Read: Intel layoffs 2025: Design engineers, software architects lose jobs - these key divisions are next What about weight loss and secondary benefits? Altimmune also highlighted significant weight loss among trial participants: 5.0% weight loss at 1.2 mg 6.2% at 1.8 mg , compared to 1.0% in placebo This positions pemvidutide alongside other GLP-1 class weight-loss drugs, a category currently generating high investor and consumer interest. Why did the stock crash despite positive results? The issue lies with the fibrosis endpoint. While there were improvements, the trial didn't reach statistical significance in its primary analysis of fibrosis reduction—a major goal in MASH treatment. Though an AI-assisted analysis showed 30.6% of patients had ≥60% reduction in fibrosis (vs. 8.2% placebo), it wasn't enough to reassure investors looking for definitive progress in this area. Are analysts still bullish on Altimmune? Yes, despite the sell-off, Wall Street remains optimistic about Altimmune's long-term prospects. The stock currently holds a "Strong Buy" rating from analysts. That suggests potential upside of nearly 190% from the current price level, assuming pemvidutide regains investor confidence in later trials. What are the short-term stock trends for ALT? Technically, ALT has been highly volatile and is currently trading in the mid-range of its 52-week band . Short-term charts show neutral-to-bearish signals , with some analysts recommending caution until the stock finds support or stabilizes. What is MASH treatment? MASH, short for Metabolic dysfunction-associated steatohepatitis, is the new name for what was previously called NASH (Non-Alcoholic Steatohepatitis). It's a serious form of fatty liver disease that occurs when fat builds up in the liver and causes inflammation and liver cell damage, potentially leading to fibrosis, cirrhosis, or even liver cancer. What's next for Altimmune and pemvidutide? Altimmune will hold an investor webcast to discuss results and plans to meet the FDA for an End-of-Phase 2 meeting by late 2025. A Phase 3 trial is still under consideration. FAQs: What caused Altimmune stock to crash after the MASH trial? The stock crashed after its MASH drug failed to show strong results in improving liver fibrosis. Is Altimmune still moving forward with pemvidutide? Yes, the company plans to meet the FDA and may start a Phase 3 trial.
